Abstract
Calcium channel blockers (CCBs) share a common mechanism of action. However, the manner in which they exert their pharmacological effects is different between subclasses. Dihydropyridine (DHP) CCBs tend to be more potent vasodilators than non-dihydropyridine (non-DHP) agents, whereas the latter have more marked negative inotropic effects. Both subclasses have a similar capacity to lower BP; however, non-DHPs appear to offer potential advantages in the management of patients with chronic kidney disease and diabetic nephropathy. Representatives of both classes are now available in fixed-dose combinations containing an ACE inhibitor, the benefits of which include effective 24-hour BP control, a reduced incidence of adverse effects, and improved adherence.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angina Pectoris / drug therapy
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Antihypertensive Agents / adverse effects
-
Antihypertensive Agents / classification
-
Antihypertensive Agents / pharmacology
-
Antihypertensive Agents / therapeutic use
-
Calcium Channel Blockers / adverse effects
-
Calcium Channel Blockers / classification
-
Calcium Channel Blockers / pharmacology
-
Calcium Channel Blockers / therapeutic use*
-
Dihydropyridines / adverse effects
-
Dihydropyridines / pharmacology
-
Dihydropyridines / therapeutic use
-
Drug Monitoring
-
Drug Therapy, Combination
-
Endothelium, Vascular / drug effects
-
Humans
-
Hypertension / drug therapy*
-
Hypertrophy, Left Ventricular / drug therapy
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Calcium Channel Blockers
-
Dihydropyridines